Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell cacinoma of the urothelium: A phase II trial of the minnie pearl cancer research network

Cancer

Volumn 103, Issue 11, 2005, Pages 2298-2303

  Hainsworth, John D ^a   Meluch, Anthony A ^a   Litchy, Sharlene ^a   Schnell, Frederick M ^b   Bearden, James D ^c   Yost, Kathleen ^d   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Central Georgia Hematology and Oncology Associates   (United States)

^c Upstate Carolina Community Clinical Oncology Program   (United States)

^d GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

Author keywords

Carboplatin; Gemcitabine; Paclitaxel; Response; Toxicity; Transitional cell carcinoma; Treatment efficacy; Urothelial carcinoma

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH; UROGENITAL TRACT TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 18844386761     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21078     Document Type: Article

References (18)

1. Scher HI, Shipley WU, Herr HW. Cancer of the bladder. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology, 5th edition. Philadelphia: Lippincott-Raven, 1997:1300-1322.
2. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer. 1989;64:2448-2458.
3. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma of the bladder: a cooperative group study. J Clin Oncol. 1992;10:1066-1073.
4. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-1055.
5. van der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol. 2000;18:3068-3077.
6. Gitlitz BJ, Baker C, Chapman Y, et al. A Phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003;98:1863-1869.
7. Roth B, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994;12:2264-2270.
8. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853-1857.
9. Stadler WM, Kuzer T, Roth B, et al. A Phase II trial of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-3398.
10. Vaughn DJ, Manola J, Dreicer R, et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction. A trial of the Eastern Cooperative Oncology Group. Cancer. 2002;95:1022-1027.
11. Moore M, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1999;17:2876-2881.
12. Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urothelial tract. An alternative therapy. Cancer. 2003;97:2180-2186.
13. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001;19:3018-3024.
14. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
15. Kaplan EL, Meier P. Nonparametric estimates from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Hainsworth JD, Burris HA, Erland JB, et al. Phase I/II trial of paclitaxel by one-hour infusion, carboplatin, and gemcitabine in the treatment of advanced non-small cell lung cancer. Cancer. 1999;85:1269-1277.
17. Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-1656.
18. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19:2527-2533.